前列腺癌患者的药物不良反应和坚持用药的预测因素。

The Canadian journal of hospital pharmacy Pub Date : 2024-10-09 eCollection Date: 2024-01-01 DOI:10.4212/cjhp.3567
Chinonyerem O Iheanacho, Valentine U Odili
{"title":"前列腺癌患者的药物不良反应和坚持用药的预测因素。","authors":"Chinonyerem O Iheanacho, Valentine U Odili","doi":"10.4212/cjhp.3567","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Adherence to therapy with prostate cancer medicines is critical for delaying the progression of disease and enhancing health outcomes.</p><p><strong>Objectives: </strong>To determine patients' medication adherence, the predictors of adherence, and the frequency and types of adverse drug reactions (ADRs) in persons with prostate cancer.</p><p><strong>Methods: </strong>A serial entry-point cross-sectional study of patients with prostate cancer was conducted in 3 cancer hospitals in Nigeria over a 12-month period (January 7, 2022, to January 3, 2023). Data on medication adherence were self-reported by patients, and data on ADRs were obtained from hospital records. Descriptive and inferential statistical analyses were performed, and <i>p</i> less than 0.05 was considered statistically significant.</p><p><strong>Results: </strong>Of the 133 study participants, most 112 (84.2%) reported high medication adherence. The cost of drugs was the most frequently reported potential barrier to adherence (<i>n</i> = 63, 47.4%). Adherence was significantly dependent on family history of cancer (df = 3, <i>F</i> = 4.557, <i>p</i> = 0.005) and health-related quality of life (HRQOL) (ß = 0.275, <i>T</i> = 2.170, <i>p</i> = 0.032) but not illness perception (ß = 0.046, <i>T</i> = 0.360, <i>p</i> = 0.72). Adverse events were observed in 36 participants (27.1%) and were deemed to be \"possible ADRs\" (<i>n</i> = 19, 53%) or \"probable ADRs\" (<i>n</i> = 17, 47%); all were nonpreventable and expected (100%), and most (<i>n</i> = 31, 86%) were within the level 1 category of severity. Loss of erection and low libido was the most frequently reported ADR (<i>n</i> = 14, 39%).</p><p><strong>Conclusions: </strong>In this study, medication adherence was high, with cost being a potential barrier to adherence. Family history of cancer and HRQOL significantly predicted medication adherence. The medications were well tolerated, and observed ADRs had minor severity. Policies targeting the reduction of cost-related factors for prostate cancer medications are essential.</p>","PeriodicalId":94225,"journal":{"name":"The Canadian journal of hospital pharmacy","volume":"77 4","pages":"e3567"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11426963/pdf/","citationCount":"0","resultStr":"{\"title\":\"Adverse Drug Reactions and Predictors of Medication Adherence in Patients with Prostate Cancer.\",\"authors\":\"Chinonyerem O Iheanacho, Valentine U Odili\",\"doi\":\"10.4212/cjhp.3567\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Adherence to therapy with prostate cancer medicines is critical for delaying the progression of disease and enhancing health outcomes.</p><p><strong>Objectives: </strong>To determine patients' medication adherence, the predictors of adherence, and the frequency and types of adverse drug reactions (ADRs) in persons with prostate cancer.</p><p><strong>Methods: </strong>A serial entry-point cross-sectional study of patients with prostate cancer was conducted in 3 cancer hospitals in Nigeria over a 12-month period (January 7, 2022, to January 3, 2023). Data on medication adherence were self-reported by patients, and data on ADRs were obtained from hospital records. Descriptive and inferential statistical analyses were performed, and <i>p</i> less than 0.05 was considered statistically significant.</p><p><strong>Results: </strong>Of the 133 study participants, most 112 (84.2%) reported high medication adherence. The cost of drugs was the most frequently reported potential barrier to adherence (<i>n</i> = 63, 47.4%). Adherence was significantly dependent on family history of cancer (df = 3, <i>F</i> = 4.557, <i>p</i> = 0.005) and health-related quality of life (HRQOL) (ß = 0.275, <i>T</i> = 2.170, <i>p</i> = 0.032) but not illness perception (ß = 0.046, <i>T</i> = 0.360, <i>p</i> = 0.72). Adverse events were observed in 36 participants (27.1%) and were deemed to be \\\"possible ADRs\\\" (<i>n</i> = 19, 53%) or \\\"probable ADRs\\\" (<i>n</i> = 17, 47%); all were nonpreventable and expected (100%), and most (<i>n</i> = 31, 86%) were within the level 1 category of severity. Loss of erection and low libido was the most frequently reported ADR (<i>n</i> = 14, 39%).</p><p><strong>Conclusions: </strong>In this study, medication adherence was high, with cost being a potential barrier to adherence. Family history of cancer and HRQOL significantly predicted medication adherence. The medications were well tolerated, and observed ADRs had minor severity. Policies targeting the reduction of cost-related factors for prostate cancer medications are essential.</p>\",\"PeriodicalId\":94225,\"journal\":{\"name\":\"The Canadian journal of hospital pharmacy\",\"volume\":\"77 4\",\"pages\":\"e3567\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-10-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11426963/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Canadian journal of hospital pharmacy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4212/cjhp.3567\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Canadian journal of hospital pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4212/cjhp.3567","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:坚持前列腺癌药物治疗对延缓疾病进展和改善健康状况至关重要:确定前列腺癌患者的用药依从性、依从性的预测因素以及药物不良反应(ADR)的频率和类型:在尼日利亚的 3 家癌症医院对前列腺癌患者进行了为期 12 个月(2022 年 1 月 7 日至 2023 年 1 月 3 日)的连续输入点横断面研究。用药依从性数据由患者自我报告,药物不良反应数据来自医院记录。研究进行了描述性和推断性统计分析,P 小于 0.05 为具有统计学意义:在 133 名研究参与者中,大多数 112 人(84.2%)表示用药依从性高。药费是最常报告的影响坚持用药的潜在障碍(63 人,占 47.4%)。坚持用药与癌症家族史(df = 3,F = 4.557,p = 0.005)和健康相关生活质量(HRQOL)(ß = 0.275,T = 2.170,p = 0.032)有明显关系,但与疾病认知(ß = 0.046,T = 0.360,p = 0.72)无关。36名参与者(27.1%)出现了不良反应,被认为是 "可能的不良反应"(19人,53%)或 "可能的不良反应"(17人,47%);所有不良反应都是不可预防和预期的(100%),大多数不良反应(31人,86%)的严重程度属于1级。勃起功能丧失和性欲低下是最常报告的不良反应(14 例,39%):结论:在这项研究中,用药依从性很高,但费用是影响用药依从性的潜在障碍。癌症家族史和 HRQOL 对用药依从性有显著影响。药物耐受性良好,观察到的不良反应严重程度较轻。针对减少前列腺癌药物费用相关因素的政策至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Adverse Drug Reactions and Predictors of Medication Adherence in Patients with Prostate Cancer.

Background: Adherence to therapy with prostate cancer medicines is critical for delaying the progression of disease and enhancing health outcomes.

Objectives: To determine patients' medication adherence, the predictors of adherence, and the frequency and types of adverse drug reactions (ADRs) in persons with prostate cancer.

Methods: A serial entry-point cross-sectional study of patients with prostate cancer was conducted in 3 cancer hospitals in Nigeria over a 12-month period (January 7, 2022, to January 3, 2023). Data on medication adherence were self-reported by patients, and data on ADRs were obtained from hospital records. Descriptive and inferential statistical analyses were performed, and p less than 0.05 was considered statistically significant.

Results: Of the 133 study participants, most 112 (84.2%) reported high medication adherence. The cost of drugs was the most frequently reported potential barrier to adherence (n = 63, 47.4%). Adherence was significantly dependent on family history of cancer (df = 3, F = 4.557, p = 0.005) and health-related quality of life (HRQOL) (ß = 0.275, T = 2.170, p = 0.032) but not illness perception (ß = 0.046, T = 0.360, p = 0.72). Adverse events were observed in 36 participants (27.1%) and were deemed to be "possible ADRs" (n = 19, 53%) or "probable ADRs" (n = 17, 47%); all were nonpreventable and expected (100%), and most (n = 31, 86%) were within the level 1 category of severity. Loss of erection and low libido was the most frequently reported ADR (n = 14, 39%).

Conclusions: In this study, medication adherence was high, with cost being a potential barrier to adherence. Family history of cancer and HRQOL significantly predicted medication adherence. The medications were well tolerated, and observed ADRs had minor severity. Policies targeting the reduction of cost-related factors for prostate cancer medications are essential.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Correction to "Discharge Opioid Prescription and Consumption Following Surgery: The POPCORN Observational Study". Development of an Environmental Audit Tool for Hospital Pharmacy. Les traitements traditionnels et les compléments alimentaires chez le patient atteint de cancer: État des lieux en Tunisie. Overcoming Challenges during Breastfeeding to Prevent Perinatal HIV Transmission in Canada: A Case Series. Piloting a Hospital Pharmacy Performance Model in the Face of Province-Wide Implementation of Activity-Based Funding in Quebec Health Care Centres.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1